Apolipoprotein E represents a potent gene‐based therapeutic target for the treatment of sporadic Alzheimer's disease
2008; Wiley; Volume: 4; Issue: 1S1 Linguagem: Inglês
10.1016/j.jalz.2007.11.012
ISSN1552-5279
Autores Tópico(s)Nuclear Receptors and Signaling
ResumoAlzheimer's & DementiaVolume 4, Issue 1S1 p. S91-S97 Perspective Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease Judes Poirier, Corresponding Author Judes Poirier judes.poirier@mcgill.ca 450-766-2010 | Fax: 450-888-4094 McGill Centre for Studies in Aging and Douglas Mental Health University Institute, Montreal, Quebec, Canada Corresponding author. Tel.: 450-766-2010; Fax: 450-888-4094. E-mail address: judes.poirier@mcgill.caSearch for more papers by this author Judes Poirier, Corresponding Author Judes Poirier judes.poirier@mcgill.ca 450-766-2010 | Fax: 450-888-4094 McGill Centre for Studies in Aging and Douglas Mental Health University Institute, Montreal, Quebec, Canada Corresponding author. Tel.: 450-766-2010; Fax: 450-888-4094. E-mail address: judes.poirier@mcgill.caSearch for more papers by this author First published: 01 January 2008 https://doi.org/10.1016/j.jalz.2007.11.012Citations: 4Read the full textAboutReferencesRelatedInformationPDFPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessClose modalShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References [1]G.W. Rebeck, J.S. Reiter, D.K. Strickland, B.T. Hyman. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 11: 1993; 575– 580 [2]D.E. Schmechel, A.M. Saunders, W.J. Strittmatter, B.J. Crain, C.M. Hulette, S.H. Joo, et al.Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA. 90: 1993; 9649– 9653 [3]U. Beffert, J. Poirier. Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Neurobiol Alzheimers Dis. 777: 1996; 166– 174 [4]J. Poirier, M.C. Delisle, R. Quirion, I. Aubert, M. Farlow, D. Lahiri, et al.Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA. 92: 1995; 12260– 12264 [5]T. Arendt, C. Schindler, M.K. Bruckner, K. Eschrich, V. Bigl, D. Zedlick, et al.Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J Neurosci. 17: 1997; 516– 529 [6]S.J. Allen, S.H. MacGowan, S. Tyler, G.K. Wilcock, A.G. Robertson, P.H. Holden, et al.Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neurosci Lett. 239: 1997; 33– 36 [7]M.K. Lai, S.W. Tsang, M. Garcia-Alloza, S.L. Minger, J.A. Nicoll, M.M. Esiri, et al.Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. Neurobiol Dis. 22: 2006; 555– 561 [8]R.C. Petersen, R.G. Thomas, M. Grundman, D. Bennett, R. Doody, S. Ferris, et al.Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 352: 2005; 2379– 2388 [9]M. Gold, S. Franke, J.S. Nye, H.R. Goldstein, B. Fijal, N. Cohen. Impact of ApoE genotype on the efficacy of galantamine for the treatment of mild cognitive impairment. Neurobiol Aging. 24: 2004; 521 [10]M.R. Farlow, Y. He, S. Tekin, J. Xu, R. Lane, H.C. Charles. Impact of APOE in mild cognitive impairment. Neurology. 63: 2004; 1898– 1901 [11]M.J. de Leon, A. Convit, O.T. Wolf, C.Y. Tarshish, S. DeSanti, H. Rusinek, et al.Prediction of cognitive decline in normal elderly subjects with 2-[F-18]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA. 98: 2001; 10966– 10971 [12]J. Poirier. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med. 9: 2003; 94– 101 [13]J. Poirier. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 17: 1994; 525– 530 [14]W.J. Strittmatter, K.H. Weisgraber, D. Huang, L.M. Dong, G.S. Salvesen, M. Pericak-Vance, et al.Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA. 90: 1993; 8098– 8102 [15]W.J. Strittmatter, A.M. Saunders, M. Goedert, K.H. Weisgraber, L.M. Dong, R. Jakes, et al.Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA. 91: 1994; 11183– 11186 [16]T.G. Ohm, M. Kirca, J. Bohl, H. Scharnagl, W. Gross, W. Marz. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience. 66: 1995; 583– 587 [17]B.P. Nathan, S. Bellosta, D.A. Sanan, K.H. Weisgraber, R.W. Mahley, R.E. Pitas. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 264: 1994; 850– 852 [18]M. Buttini, M. Orth, S. Bellosta, H. Akeefe, R.E. Pitas, T. Wyss-Coray, et al.Expression of human apolipoprotein E3 or E4 in the brains of apoE −/− mice: isoform-specific effects on neurodegeneration. J Neurosci. 19: 1999; 4867– 4880 [19]M. Tolar, M.A. Marques, J.A. Harmony, K.A. Crutcher. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J Neurosci. 17: 1997; 5678– 5686 [20]J. Poirier, A. Minnich, J. Davignon. Apolipoprotein E, synaptic plasticity and Alzheimer's disease. Ann Med. 27: 1995; 663– 670 [21]M. Mulder, P.J. Jansen, B.J. Janssen, W.D. van de Berg, H. van der Boom, L.M. Havekes, et al.Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. Neurobiol Dis. 16: 2004; 212– 219 [22]E. Masliah, M. Mallory, N. Ge, M. Alford, I. Veinbergs, A.D. Roses. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol. 136: 1995; 107– 122 [23]I. Veinbergs, E. Masliah. Synaptic alterations in apolipoprotein E knockout mice. Neuroscience. 91: 1999; 401– 403 [24]D. Champagne, J. Rochford, J. Poirier. Effect of apolipoprotein E deficiency on reactive sprouting in the dentate gyrus of the hippocampus following entorhinal cortex lesion: role of the astroglial response. Exp Neurol. 194: 2005; 31– 42 [25]D. Champagne, J.B. Dupuy, J. Rochford, J. Poirier. Apolipoprotein E knockout mice display procedural deficits in the Morris water maze: analysis of learning strategies in three versions of the task. Neuroscience. 114: 2002; 641– 654 [26]I. Veinbergs, M. Mante, M.W. Jung, E. Van Uden, E. Masliah. Synaptotagmin and synaptic transmission alterations in apolipoprotein E-deficient mice. Prog Neuropsychopharmacol Biol Psychiatry. 23: 1999; 519– 531 [27]J. Grootendorst, A. Bour, E. Vogel, C. Kelche, P.M. Sullivan, J.C. Dodart, et al.Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior. Behav Brain Res. 159: 2005; 1– 14 [28]S. Chapman, T. Sabo, A.D. Roses, D.M. Michaelson. Reversal of presynaptic deficits of apolipoprotein E-deficient mice in human apolipoprotein E transgenic mice. Neuroscience. 97: 2000; 419– 424 [29]D.M. Holtzman, K.R. Bales, S. Wu, P. Bhat, M. Parsadanian, A.M. Fagan, et al.Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest. 103: 1999; R15– R21 [30]T. Wisniewski, A. Golabek, E. Matsubara, J. Ghiso, B. Frangione. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun. 192: 1993; 359– 365 [31]U. Beffert, N. Aumont, D. Dea, S. Lussier-Cacan, J. Davignon, J. Poirier. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Brain Res Mol Brain Res. 68: 1999; 181– 185 [32]G. Utermann, U. Langenbeck, U. Beisiegel, W. Weber. Genetics of the apolipoprotein E system in man. Am J Hum Genet. 32: 1980; 339– 347 [33]E.H. Corder, A.M. Saunders, N.J. Risch, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell Jr, et al.Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 7: 1994; 180– 184 [34]J. Poirier. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging. 26: 2005; 355– 361 [35]H. Blanche, L. Cabanne, M. Sahbatou, G. Thomas. A study of French centenarians: are ACE and APOE associated with longevity? C R Acad Sci III. 324: 2001; 129– 135 [36]G.B. Frisoni, J. Louhija, C. Geroldi, M. Trabucchi. Longevity and the epsilon2 allele of apolipoprotein E: the Finnish Centenarians Study. J Gerontol [A] Biol Sci Med Sci. 56: 2001; M75– M78 [37]P. Bertrand, J. Poirier, T. Oda, C.E. Finch, G.M. Pasinetti. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res. 74: 1995; 178– 184 [38]J. Poirier. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging. 26: 2005; 355– 361 [39]C.E. Finch, C.B. Stanford. Meat-adaptive genes and the evolution of slower aging in humans. Q Rev Biol. 79: 2004; 3– 50 [40]D.J. Stone, I. Rozovsky, T.E. Morgan, C.P. Anderson, C.E. Finch. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. J Neurosci. 18: 1998; 3180– 3185 [41]J. Rogers, L.C. Kirby, S.R. Hempelman, D.L. Berry, P.L. McGeer, A.W. Kaszniak, et al.Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43: 1993; 1609– 1611 [42]R. Aleong, N. Aumont, D. Dea, J. Poirier. Non-steroidal anti-inflammatory drugs mediate increased in vitro glial expression of apolipoprotein E protein. Eur J Neurosci. 18: 2003; 1428– 1438 [43]M.E. Risner, A.M. Saunders, J.F. Altman, G.C. Ormandy, S. Craft, I.M. Foley, et al.Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenom J. 6: 2006; 246– 254 [44]L. Yue, N. Rasouli, G. Ranganathan, P.A. Kern, T. Mazzone. Divergent effects of peroxisome proliferator-activated receptor gamma agonists and tumor necrosis factor alpha on adipocyte ApoE expression. J Biol Chem. 279: 2004; 47626– 47632 [45]J. Poirier, M. Panisset. Apolipoprotein E: a novel therapeutic target for the treatment of Alzheimer's disease. Adv Exp Med Biol. 51: 2002; 36– 42 [46]J. Poirier. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med. 9: 2003; 94– 101 [47]M.S. Burkhardt, J.K. Foster, S. Laws, L.D. Baker, S. Craft, S. Gandy, et al.Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4. J Alzheimers Dis. 6: 2004; 221– 228 [48]J. Poirier. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging. 26: 2005; 355– 361 [49]D. Champagne, D. Pearson, D. Dea, J. Rochford, J. Poirier. The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease. Neuroscience. 121: 2003; 99– 110 [50]J. Poirier. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med. 9: 2003; 94– 101 Citing Literature Volume4, Issue1S1Leon Thal Symposium on the Prevention of DementiaJanuary 2008Pages S91-S97 ReferencesRelatedInformation RecommendedNeuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigmsKrista L. Lanctôt, Joan Amatniek, Sonia Ancoli-Israel, Steven E. Arnold, Clive Ballard, Jiska Cohen-Mansfield, Zahinoor Ismail, Constantine Lyketsos, David S. Miller, Erik Musiek, Ricardo S. Osorio, Paul B. Rosenberg, Andrew Satlin, David Steffens, Pierre Tariot, Lisa J. Bain, Maria C. Carrillo, James A. Hendrix, Heidi Jurgens, Brendon Boot, Alzheimer's & Dementia: Translational Research & Clinical InterventionsToward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseReisa A. Sperling, Paul S. Aisen, Laurel A. Beckett, David A. Bennett, Suzanne Craft, Anne M. Fagan, Takeshi Iwatsubo, Clifford R. Jack, Jeffrey Kaye, Thomas J. Montine, Denise C. Park, Eric M. Reiman, Christopher C. Rowe, Eric Siemers, Yaakov Stern, Kristine Yaffe, Maria C. Carrillo, Bill Thies, Marcelle Morrison-Bogorad, Molly V. Wagster, Creighton H. Phelps, Alzheimer's & DementiaChallenges in clinical research on Alzheimer's disease: Leon Thal's legacyRonald C. Petersen, Alzheimer's & DementiaA quarter century of advancing treatment for Alzheimer's disease with Leon J. ThalMichael Grundman, Alzheimer's & Dementia Metrics Citations: 4 Details © 2008 The Alzheimer's Association Publication History Issue Online: 01 January 2008 Version of Record online: 01 January 2008
Referência(s)